Harbour Investments’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Harbour Investments’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,688	Closed	-$129K	–	3870
2025 Q2	$129K	Hold	5,688	–	–	﹤0.01%	1377
2025 Q1	$123K	Sell	5,688 -1,200	-17%	-$27.3K	﹤0.01%	1328
2024 Q4	$155K	Sell	6,888 -2,675	-28%	-$66.1K	﹤0.01%	1153
2024 Q3	$256K	Buy	9,563 +2,895	+43%	+$77.7K	0.01%	915
2024 Q2	$174K	Buy	+6,668	New	+$171K	0.01%	999

Other funds holding THNR

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments's THNR Position: Q3 2025 in Review

Harbour Investments sold out of Amplify Weight Loss Drug & Treatment ETF (THNR) in Q3 2025, closing a stake of 5,688 shares — an estimated $129K sold.

Harbour Investments first reported a position in THNR in Q2 2024 and held it in 5 quarters. The position peaked at $256K in Q3 2024. 2 funds tracked by Wall St. Rank hold THNR as of Q3 2025.

Harbour Investments reported no remaining Amplify Weight Loss Drug & Treatment ETF position as of Q3 2025 after selling out during the quarter.
Harbour Investments sold 5,688 Amplify Weight Loss Drug & Treatment ETF shares in Q3 2025, an estimated $129K.
Harbour Investments first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q2 2024 and held it in 5 quarters.
Harbour Investments's Amplify Weight Loss Drug & Treatment ETF position peaked at $256K in Q3 2024.
2 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q3 2025.

Based on Harbour Investments's 13F filing for Q3 2025, filed 12 Nov 2025.